Discover Top 50 Companies in Polycystic Kidney Disease: Global Share, Market Size, Revenue Report (2024-2035).
RELEASE DATE: Aug 2025 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Polycystic Kidney Disease Market Size is projected to Grow from USD 0.62 Billion in 2024 to USD 1.19 Billion by 2035, at a CAGR of 6.74 % during the forecast period 2025–2035. The polycystic kidney disease market holds future opportunities in gene therapy, targeted drug development, early diagnostic tools, and personalized treatments, driven by rising disease prevalence and advancements in renal healthcare technologies.
Introduction
Polycystic kidney disease (PKD) is a genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys, leading to kidney enlargement and impaired function over time. The PKD market involves diagnostic tools, treatment options, and ongoing research aimed at managing or slowing disease progression. Key driving factors for market growth include the increasing prevalence of genetic and chronic kidney diseases, advancements in imaging and diagnostic techniques, rising awareness and screening programs, and growing investments in biotechnology and gene therapy. Moreover, the demand for novel and personalized therapies continues to push innovation in this space.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of the Polycystic Kidney Disease market.
Polycystic Kidney Disease Market Size & Statistics
The Market Size for Polycystic Kidney Disease Was Estimated to be Worth USD 0.62 Billion in 2024.
The Market Size is Going to Expand at a CAGR of 6.74 % Between 2025 and 2035.
The Global Polycystic Kidney Disease Market Size is Anticipated to Reach USD 1.19 Billion by 2035.
North America is expected to generate the highest demand during the forecast period in the Polycystic Kidney Disease Market.
Asia Pacific is expected to grow the fastest during the forecast period in the Polycystic Kidney Disease Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the polycystic kidney disease market. The area is projected to see the quickest expansion in the worldwide polycystic kidney disease (PKD) market owing to increasing chronic kidney disease rates, healthcare funding, and enhanced access to cutting-edge diagnostics and therapies. This expansion is fueled by a substantial population, the need for early diagnosis, and groundbreaking treatments.
North America is expected to generate the highest demand during the forecast period in the polycystic kidney disease market. The area is set to lead the worldwide polycystic kidney disease (PKD) market thanks to its developed healthcare facilities, strong awareness, emphasis on research, prominent pharmaceutical firms, active clinical trials, groundbreaking treatments such as tolvaptan, and dedicated healthcare services, supported by considerable investment
Top 5 Emerging Kidney Disease Startups Impacting the Pharma Industry
1. Klotho Therapeutics – Chronic Kidney Disease
Chronic kidney disease and acute renal failure are two disorders stemming from inadequate kidney function. Any decrease in klotho levels, a naturally occurring protein found in the kidneys, leads to accelerated aging and affects the kidney’s processing abilities. Startups are creating solutions that enhance the klotho levels in the human body and consequently boost kidney function. Klotho Therapeutics, a BioTech startup located in the US, creates recombinant forms of human klotho protein for the treatment of chronic kidney disease. The approach has been shown to greatly decrease the likelihood of chronic kidney disease (CKD) and acute renal failure (ARF) in animal studies. It also shows potential for treating other conditions, including sarcopenia, cancer, and age-related diseases.
2. Invizius – Dialysis
Dialysis therapy replicates the kidney's roles in filtering and managing the impurities within the bloodstream. The frequency of dialysis differs for every patient, based on the severity of their kidney condition. Nonetheless, there exists a danger of developing cardiovascular issues as a result of an immune reaction to the foreign implant. Startups are developing solutions that enhance the safety of dialysis procedures and elevate the quality of life for patients. The UK company Invizius develops a priming solution for dialysis membranes. H-Guard integrates a coating agent, a surface protein obtained from Streptococcus pneumoniae, to cover the dialysis membrane. This stops immune cells from triggering inflammation upon identifying foreign substances, thus lowering the risk of cardiovascular issues in patients receiving dialysis.
3. Chinook Therapeutics – Berger’s Disease
Immunoglobulin A (IgA) nephropathy, referred to as Berger’s disease, is a renal condition resulting from an abnormal accumulation of IgA in the kidneys. The localized inflammation caused by this IgA accumulation prevents the kidneys from properly filtering waste from the blood. This presents several complications, including elevated blood pressure, high cholesterol, along with swelling in the eyelids, feet, and abdomen. Startups are creating targeted blocker medications to detect and address Berger's disease prior to the appearance of symptoms. The Canadian startup Chinook Therapeutics is creating innovative drug treatments for various kidney disorders, including Berger’s disease. The primary candidate of the startup, Atrasentan, is a selective inhibitor of the ETA receptor and aids in diminishing kidney inflammation and fibrosis. Furthermore, the startup is creating medications for polycystic kidney disease along with other kidney conditions.
4. Oxalo Therapeutics – Kidney Stones
Certain gastrointestinal conditions result in excessive absorption of oxalate. The buildup of oxalate, uric acid, and calcium on the inner surface of the kidney leads to the creation of crystalline particles, commonly referred to as kidney stones. While shockwave lithotripsy can treat this by fragmenting the particles into smaller pieces, it is ineffective for larger and harder stones in the kidneys. Startups create treatment options to tackle the calcification of oxalates within the kidneys. The American startup Oxalo Therapeutics is developing peptide-based treatments for kidney stones. The primary candidate of the startup is an oral medication that activates the body's natural mechanism for regulating intestinal oxalate, lowering oxalate levels in both plasma and urine. This approach efficiently addresses primary hyperoxaluria, secondary hyperoxaluria, and hyperoxalemia.
5. Kantum Bio – Acute Kidney Injury (AKI)
Individuals, particularly adults, who are receiving cardiac surgery face a significant risk of developing acute kidney injury. Individuals with AKI face elevated mortality rates as the condition significantly impairs the body’s capacity to eliminate waste from the bloodstream. Progress in nephrology allows startups to pinpoint targets for creating small molecule drugs aimed at preventing acute kidney injury in patients. The startup Kantam Bio, located in the US, creates biomarkers for the early detection of AKI. The primary drug candidate of the startup, KB-1801, is presently undergoing preclinical development to prevent acute kidney injury caused by cardiac surgery. The medication inhibits the activation of uridine diphosphate (UDP) glucose or P2Y14 receptor, which stops inflammation in the kidneys, lungs, and uterus. Furthermore, the startup is creating therapies and diagnostic tools for delayed graft function disorder, cystic fibrosis, and inflammatory conditions of the female reproductive system.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the polycystic kidney disease market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 16 Companies Leading the Polycystic Kidney Disease Market
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi
- Johnson & Johnson
- Novartis AG
- AbbVie Inc.
- AstraZeneca
- Merck & Co., Inc.
- Pfizer Inc.
- Bayer AG
- Reata Pharmaceuticals, Inc.
- Eli Lilly and Company
- Galapagos NV
- Vertex Pharmaceuticals
- Bristol-Myers Squibb
- GlaxoSmithKline plc (GSK)
- Others
1. Otsuka Pharmaceutical Co., Ltd.
Headquartered in Tokyo, Japan
Otsuka Pharmaceutical is a global healthcare company dedicated to innovative drug development and nutraceuticals. Best known for its contributions in nephrology, psychiatry, and oncology, the company has made significant advancements in the treatment of polycystic kidney disease (PKD), particularly through its drug tolvaptan. Otsuka emphasizes a holistic approach to health, integrating pharmaceuticals and functional food products. With a strong commitment to research and development, it operates in over 30 countries and strives to address unmet medical needs through science-driven innovation and ethical business practices.
2. Sanofi
Headquartered in Paris, France
Sanofi is a multinational pharmaceutical company. It focuses on human health, offering a wide range of prescription medicines, vaccines, and consumer healthcare products. In nephrology and rare diseases, Sanofi is expanding its research to include conditions like PKD. The company is known for its work in immunology, oncology, diabetes, and vaccines through its Sanofi Pasteur division. With a strong global presence and a commitment to digital transformation and innovation, Sanofi invests heavily in R&D and sustainability initiatives to deliver impactful therapies across diverse therapeutic areas.
3. Johnson & Johnson
Headquartered in New Brunswick, New Jersey, USA
Johnson & Johnson is one of the world’s largest healthcare companies. It operates through three main segments: pharmaceuticals, medical devices, and consumer health products. Its pharmaceutical arm, Janssen, explores therapeutic solutions in nephrology and rare diseases like PKD. J&J is renowned for its patient-centric innovation, long-standing commitment to R&D, and global outreach. The company maintains a robust pipeline in chronic disease management and cutting-edge treatments, while also placing strong emphasis on ethical practices, accessibility, and healthcare equity worldwide.
4. Novartis AG
Headquartered in Basel, Switzerland
Novartis AG is a leading global pharmaceutical company focused on innovative medicines. The company is deeply invested in gene and cell therapy, making it a key player in rare disease treatment, including research into polycystic kidney disease. Novartis offers a broad portfolio across oncology, immunology, cardiology, and neuroscience. With a mission to reimagine medicine, Novartis leverages data science and advanced technology to accelerate drug development. Its commitment to sustainability, patient access, and breakthrough therapies positions it at the forefront of modern healthcare advancement.
5. AbbVie Inc.
Headquartered in North Chicago, Illinois, USA
AbbVie is a global biopharmaceutical company known for its focus on innovation in complex and chronic conditions. The company’s therapeutic areas include immunology, oncology, neuroscience, and renal care. AbbVie is expanding its presence in nephrology and exploring therapies for genetic diseases such as PKD. With a strong pipeline of biologics and targeted therapies, AbbVie integrates scientific expertise and patient care to deliver high-impact treatments. The company also emphasizes corporate responsibility, including affordable access to medicines, research partnerships, and healthcare innovation.
Are you ready to discover more about the polycystic kidney disease market?
The report provides an in-depth analysis of the leading companies operating in the global polycystic kidney disease market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Otsuka Pharmaceutical Co., Ltd.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Sanofi
- Johnson & Johnson
- Novartis AG
- AbbVie Inc.
- AstraZeneca
- Merck & Co., Inc.
- Pfizer Inc.
- Bayer AG
- Reata Pharmaceuticals, Inc.
- Eli Lilly and Company
- Galapagos NV
- Vertex Pharmaceuticals
- Bristol-Myers Squibb
- GlaxoSmithKline plc (GSK)
- Others
Conclusion
The polycystic kidney disease market is undergoing a significant transformation driven by scientific innovation, growing awareness, and investment in targeted therapies. With advancements in gene therapy, early diagnostics, and personalized treatment approaches, the landscape is rapidly evolving to meet rising global healthcare needs. Emerging biotech firms and established pharmaceutical companies alike are accelerating research efforts to address unmet clinical challenges. Regional markets are also witnessing shifts, with Asia Pacific showing strong growth potential and North America leading in demand. As the industry moves forward, stakeholders must leverage strategic insights to capitalize on upcoming opportunities and shape the future of renal healthcare.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?